ArticleBioinformatics (Oxford, England)2026
Trajectory-guided dimensionality reduction for multi-sample single-cell RNA-seq data reveals biologically relevant sample-level heterogeneity.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
motivationDimensionality reduction for single-cell RNA-sequencing (scRNA-seq) data involving multiple biological samples presents a significant analytical challenge.
resultsWe introduce MUlti-Sample Trajectory-Assisted Reduction of Dimensions (MUSTARD), an innovative trajectory-guided dimensionality reduction method specifically designed for multi-sample, multi-condition scRNA-seq data. By integrating pseudotemporal information, MUSTARD provides a comprehensive unsupervised approach that simultaneously captures major gene expression variation patterns along pseudotime trajectories and across multiple samples, facilitating the discovery of biologically meaningful sample heterogeneity, endotypes, and associated gene markers and modules. In data-driven simulations, MUSTARD outperformed existing methods in distinguishing sample groups, achieving superior out-of-sample prediction accuracy. In two COVID-19 datasets and a tuberculosis dataset, MUSTARD identified components linked to symptom severity, batch effect, and other known biological variations, with notable overlap in immune response genes across the two independent COVID-19 datasets. These results underscore MUSTARD's flexibility and power in identifying biologically relevant sample heterogeneity across diverse datasets. AVAILABILITY AND IMPLEMENTATION: The R package MUSTARD with a detailed user manual is publicly available at https://github.com/haotian-zhuang/MUSTARD and Zenodo (DOI: 10.5281/zenodo.18293392). The source code to reproduce the results in this paper is available at https://github.com/haotian-zhuang/MUSTARD_Paper and Zenodo (DOI: 10.5281/zenodo.18293392).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.